HealthPolitics

STAT+: Five biotech updates to read after ESMO this weekend

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/10/2026, 06:36:26 UTC.

Briefings

Moderna CEO Stéphane Bancel announced at the ESMO meeting in Madrid that his company is advancing its personalized cancer vaccine, intismeran, beyond melanoma. The CEO stated the team is racing to submit the vaccine for FDA approval in 2027 and is preparing for aggressive testing in other cancer types.

Key points

• Moderna CEO Stéphane Bancel is advancing the personalized cancer vaccine intismeran beyond melanoma following a successful Phase 3 trial.
• The vaccine is expected to receive FDA approval in 2027, with testing planned for additional cancer types.

Context

This finding comes from an interview with STAT at the ESMO meeting in Madrid, where Moderna CEO Stéphane Bancel discussed the company's strategic expansion of its cancer vaccine portfolio.

Limitations

The evidence is limited to a single interview with Stéphane Bancel at the ESMO meeting in Madrid. Specific details about the trial results, exact cancer types beyond melanoma, or the timeline for FDA submission are not fully detailed in the source.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 27/10/2026, 07:50:57 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeih5dbwgyflgo6jgn62cztpyrbbn7hf36xvsfsvvrsbodfqenkyisy